National Institute of Allergy and Infectious Diseases 5R01AI173328-04

Identification of new inhibitors of essential functions in M. tuberculosis by high-throughput metabolic profiling

This award funds research to identify new inhibitors targeting essential functions in Mycobacterium tuberculosis by leveraging high-throughput metabolic profiling combined with CRISPR technology and computational tools to annotate drug modes of action and gene functions, addressing the urgent need for novel antimicrobials against multi-drug resistant tuberculosis.

Description

The project aims to discover new antimicrobials for multi-drug resistant tuberculosis by using a combined computational and experimental strategy involving CRISPR technology and non-targeted metabolomics to perform high-throughput functional annotations of anti-TB compounds with unknown modes of action. This includes building a metabolic response database of Mtb to gene knockdowns, transcription factor overexpression, and growth inhibitors, categorizing drug actions, generating hypotheses about drug modes of action, and validating hits, as well as functionally annotating genes with unknown functions in M. tuberculosis.

View original record